CeriBell, Inc. reported $102M of revenue over the trailing twelve months, +32% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $102M (to Q2 2026). Net income: −$66M, trailing twelve months to Q2 2026. Free cash flow: −$55M, trailing twelve months to Q2 2026. Operating margin: −68%, trailing twelve months to Q2 2026.

CBLLCeriBell, Inc.

Healthcare

$23.15+96% 1Y

$23.15

$10.9252 weeks$25.01

CBLL as reported

CeriBell, Inc. reported $102M of revenue over the trailing twelve months, +32% on the year before. 9 reported series are charted on this page, each one as filed.

$102M

Revenue, trailing twelve months · to Q2 2026 · +32% against the twelve months before

Net income: −$66M
Net income · +34% year on year · trailing twelve months to Q2 2026
Free cash flow: −$55M
Free cash flow · +42% year on year · trailing twelve months to Q2 2026
Operating margin: −68%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CBLL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$102M	+32%	Q2 2026
Net income	−$66M	+34%	Q2 2026
EPS	−$1.76	+83%	Q2 2026
Gross margin	89%	n/a	Q2 2026
Operating margin	−68%	n/a	Q2 2026
Net margin	−64%	n/a	Q2 2026
ROE	−40%	n/a	Q2 2026
ROA	−32%	n/a	Q2 2026
Free cash flow	−$55M	+42%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.